Today BrightInsight announced our $101M Series C funding led by @gcvp! This funding will enable #BrightInsight to continue our hypergrowth, and to support the development and launch of game-changing #digitalhealth solutions for our customers. x.com/home

Enjoyed tonight's #HLTHAfterHours conversation with Toyin Ajayi, Kal Patel, Adam Seabrook, Ryan Gillooly, and @jody_tropeano. Thank you for having me! joinclubhouse.com/event/mWN7gA6B

Attending #DTxEast? Stop by our booth to meet with the #BrightInsight team! We also have a virtual booth for all those attending virtually.

Excited to be at #DTxEast today! I will be moderating the panel: Understanding the End-to-End Process of Building a Regulated Software as a Medical Device (SaMD) today at 12:50 EST. Come join us for an insightful discussion around the end-to-end process of SaMD. #brightinsight

“In the early days of Pharma, we didn’t have device groups- it was an afterthought. Now that would be preposterous. Digital will be the same, becoming an integrated part of the drug lifecycle development from patient identification to dosing to adherence.” - Kal Patel #DTxEast

What is the greatest barrier to #digitalhealth adoption? Clinicians. It takes 17 years to change the practice of medicine. That’s 17 years after data and evidence exists around new best practices. 🤯 Chris Wasden #dtxeast

Attending #DTxWest? Be sure to catch the Discussion Panel: Minding the Gap: How to align expectations and realities when building Software as a Medical Device at 3:40PM PST today!

Dave Matthews (David Matthews) kicks off our #DTxWest panel and shares recent stat: “100% of #digitalhealth leaders agree that #SaMD initiatives take longer and cost more than originally believed.”

.@paularthurupham of Roche/Genentech talks about measuring ROI of #SaMD by thinking about the “Return to Patient” and the benefits you’re delivering to patients. #DTxWest

Our own Kal Patel is joined by Brad Gescheider from Sanofi Wainwright Fishburn from Cooley LLP and jameslu from Helix to discuss partnering strategies for success in digital health 🤩 #BIO2022

“Software as a Medical Device “SaMD” will be foundational to generating value around therapies and devices, and it’s at the heart of what we do BrightInsight ” - Kal Patel shares during #BIO2022

This year is shaping up to be an inflection point for #digitalhealth. Many investors expect digital health dollars in 2023 to return to 2020 levels. I’ve been reflecting on my 10 years in the industry. Here are some learnings from what worked and didn’t. bit.ly/3VWaYqq

What an exciting Q2 for #BrightInsight! 🤩🚀 Some highlights includes earning the Frost & Sullivan IoT Healthcare Solutions 2023 Global Company of the Year Award, receiving the CE mark and more. Here’s a video recap of our Q2 highlights! 🌟 youtu.be/_ZtYZtcHGP8

When it comes to #digitalhealth, the pharmaceutical industry seems to be stricken with FOMU—fear of messing up. It’s not without reason. After all, patients’ lives are on the line, and pharma executives face a host of other high-pressure risks. Kal Patel Forbes

But #pharma would do well to trade its FOMU for FOMO—fear of missing out—because #digitalhealth technologies can unlock huge amounts of value while addressing critical adoption and adherence issues. Kal Patel Forbes bit.ly/44RJXsO

Adoption and scaling of #digitalhealth remains a significant challenge for life science companies. Explore how you can make your digital solutions stand out in our new white paper, Go-to-Market Strategies for Patient-Facing Digital Health Solutions: bit.ly/3SZukwQ

We are proud to share that BrightInsight was awarded 307th place in the Deloitte Technology #Fast500, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America! 🏆

This recognition was fueled by BrightInsight’s multiple global app launches, product and platform enhancements and new partnerships in 2023, all of which contributed to our 431% revenue growth. bit.ly/3sMrAs9

We are excited to announce that BrightInsight has been named to Forbes prestigious ranking of America’s Best Startup Employers for 2024 for the second year in a row! 🏆 brightinsight.com/blog/brightins…

In this interview, Jamie Eisinger Burgess spoke with Justin Butler, Partner at Eclipse Ventures, about the firm’s investment thesis when it comes to GenAI, the potential of GenAI & digital to improve patient-provider communication, and how AI- powered technologies will enable data sharing.